MedTrace Logo

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

NCT01309204 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1184

Last updated 2014-04-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to evaluate the safety and efficacy of Brinzolamide/Brimonidine fixed combination in lowering intraocular pressure (IOP) relative to each of its individual active constituents instilled concomitantly (Brinzolamide+Brimonidine) in patients with open-angle glaucoma or ocular hypertension.

Conditions

Interventions

DRUG

Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension

DRUG

Vehicle

Inactive ingredients used as a placebo for masking purposes

DRUG

Brinzolamide 1% ophthalmic suspension

DRUG

Brimonidine tartrate 0.2% ophthalmic solution

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Steve Burmaster, PhD · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2013-01-31
Completion
2013-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01309204 on ClinicalTrials.gov